Hamai Yoich, Yoshiya Tomoharu, Hihara Jun, Emi Manabu, Furukawa Takaoki, Yamakita Ichiko, Ibuki Yuta, Okada Morihito
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
J Thorac Dis. 2019 Jun;11(6):2470-2478. doi: 10.21037/jtd.2019.05.67.
Cisplatin (CDDP) is an important chemotherapeutic drug for treating esophageal cancer that often induces nausea and vomiting. Rikkunshito (RKT), a traditional Japanese herbal medicine, can increase levels of plasma ghrelin, which is an orexigenic gut hormone that can alleviate chemotherapy-induced nausea and vomiting (CINV) and anorexia.
This prospective randomized crossover study included 20 patients with esophageal cancer who were administered with CDDP-based chemotherapy. Ten of them were assigned to group A [1st course: with RKT 7.5 g/day on days 1-14; 2nd course: without RKT (control)] and 10 were assigned to group B [1st course: without RKT (control); 2nd course: with RKT 7.5 g/day on days 22-35]. Food intake and levels of plasma acylated ghrelin (AG) were compared between the control and RKT courses.
Data from 18 patients were included in this analysis, as chemotherapy was immediately stopped due to deteriorating renal function in one patient and intracerebral bleeding in another. The median rate at which food intake decreased between days 4 and 6 was considerably lower in the course with, than without RKT (2% 30%; P=0.02). Median levels of AG significantly increased from days 3 to 8 in patients in both courses with and without RKT (9.6 to 15.7 fmol/mL, P<0.0001; control, 10.2 to 17.8, P=0.0002). The rate at which median plasma AG levels increased from days 3 to 8 tend to be higher in the RKT, than in the control course (68% 48%, P=0.08).
RKT can improve CDDP-induced, delayed-onset anorexia and increase plasma AG levels among patients with esophageal cancer who undergo highly emetogenic chemotherapy (HEC).
顺铂(CDDP)是治疗食管癌的一种重要化疗药物,常引起恶心和呕吐。日本传统草药理气剂(RKT)可提高血浆胃饥饿素水平,胃饥饿素是一种促食欲的肠道激素,可减轻化疗引起的恶心和呕吐(CINV)及厌食症。
这项前瞻性随机交叉研究纳入了20例接受基于顺铂化疗的食管癌患者。其中10例被分配到A组[第1疗程:第1 - 14天服用7.5克/天的理气剂;第2疗程:不服理气剂(对照)],10例被分配到B组[第1疗程:不服理气剂(对照);第2疗程:第22 - 35天服用7.5克/天的理气剂]。比较对照疗程和有理气剂疗程之间的食物摄入量及血浆酰基化胃饥饿素(AG)水平。
本分析纳入了18例患者的数据,因为有1例患者因肾功能恶化、另1例因脑出血而立即停止化疗。在有理气剂的疗程中,第4至6天食物摄入量下降的中位数率明显低于无理气剂的疗程(2%对30%;P = 0.02)。在有理气剂和无理气剂的两个疗程中,患者从第3天到第8天AG的中位数水平均显著升高(分别从9.6升至15.7飞摩尔/毫升,P < 0.0001;对照组从10.2升至17.8,P = 0.0002)。从第3天到第8天,血浆AG中位数水平升高的速率在有理气剂疗程中往往高于对照疗程(68%对48%,P = 0.08)。
理气剂可改善顺铂引起的延迟性厌食症,并提高接受高致吐性化疗(HEC)的食管癌患者的血浆AG水平。